Individuals with impaired lung function trajectories experience a higher burden of respiratory symptoms, including wheeze and ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

Q4 2024 Earnings Call Transcript February 27, 2025 Verona Pharma plc misses on earnings expectations. Reported EPS is $-0.4 ...

Specialty pharmacy expands access to an innovative, steroid-free treatment NEW PROVIDENCE, NJ, UNITED STATES, March 3, 2025 /EINPresswire / -- ...

Discover 7 surprising ways asthma develops in adulthood – from workplace exposures to hormonal shifts. Frequently begins ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

The drug was administered twice-daily using a nebuliser as a chronic maintenance therapy for people with COPD in the ENHANCE ... and is thought to combine bronchodilator and anti-inflammatory ...

COPD is the third leading cause of death worldwide ... a third compared to placebo when added to standard therapies like bronchodilators, inhaled or oral corticosteroids to reduce inflammation ...

Delhi NCR is witnessing a sharp rise in cases of influenza, including swine flu, with many residents experiencing prolonged ...

Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Verona Pharma in a research note issued on Friday, February 28th. HC Wainwright analyst R.

Verona Pharma (NASDAQ:VRNA – Free Report) had its price objective increased by HC Wainwright from $60.00 to $75.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...

US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...